Paladin Labs, Inc.
Please contact Sales at: (212) 520-2765 or email PharmaNewsSales@informa.com
Latest From Paladin Labs, Inc.
After launching in the US last year, the teriparatide product developed by Pfenex and Alvogen has been introduced in Europa, via commercialization partner Theramex, beginning with Germany.
After accumulating technologies to develop off-the-shelf, allogeneic NK cell therapies over the past decade, Korea's GC LabCell is now tapping into the global market as US partner Artiva begins clinical trials of its lead asset.
Trial of high-need gene therapy set to restart following the deaths of several participants and the lifting of a clinical hold imposed by the US FDA last year.
Olema launched this year’s 75th US biopharma IPO. Also, investments in regenerative medicines reached a new high, Qiming closed a $1.2bn China-focused VC fund, D3 Bio led recent venture deals with a $200m round, and Bausch sold $2bn worth of notes to pay down near-term debts.
- Specialty Pharmaceuticals
- Other Names / Subsidiaries
- Allon Therapeutics, Inc.
- Ativa Pharma S.A,
- Labopharm Inc.
- ViRexx Medical Corp.
- Triton Pharma Inc.